Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Showing public results only.
A filing-led Datavault AI deep dive covering Q1 2026 results, product architecture, RWA tokenization, SanQtum GPU infrastructure, NYIAX/CyberCatch/DelivMeds optionality, HELMEX structured financing, dilution, and the proof gates that matter next.
OpenA beginner-friendly, fact-based DVLT brief on HELMEX, the UK address controversy, the non-binding $2B term sheet, the $25M payment, dilution, and board rights.
OpenDatavault AI's June 4 Form 8-K turns the structured financing story into a cash, dilution, control, and approval proof gate.
OpenA filing-backed DVLT update explaining Vivasor's Form 3 initial position, Form 4 20M-share sale, Schedule 13G remaining stake, and the proof gate investors should monitor.
OpenA beginner-friendly translation of Datavault AI's $2.0B structured financing term sheet, including term sheet status, dilution, tranches, the $25M payment, share-value math, and shareholder proof gates.
OpenDatavault AI's $2.0B structured financing term sheet could give the company a collateral base and global tokenization mandate, but the deal is non-binding, potentially dilutive, and loaded with proof gates.
OpenDatavault AI's Perpetuals.com agreement gives its RWA tokenization story a needed liquidity layer, but the investment case still depends on listings, trading volume, fee recognition, and cash collection.
OpenA highly bullish but source-gated Datavault AI analysis framing DVLT as a speculative public option on AI data ownership, tokenization, SanQtum edge infrastructure, CyberCatch optionality, and contract-to-cash proof gates.
OpenA source-backed Datavault AI analysis that separates the real May 2026 institutional financing signal from unsupported dark-pool, hedge-fund, bank-upgrade, and supply-crunch claims.
OpenA filing-led Datavault AI Q1 2026 earnings thesis focused on recognized revenue, tokenization contracts, cash conversion, losses, liquidity, and dilution risk.
Open20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
OpenAmerican Integrity is a newly public but seasoned Florida residential property insurer. The latest filings show 437,308 policies in force, $974.8 million of in-force premium, a 75.0% Q1 combined ratio and a reduced non-catastrophe quota share that lets AII keep more economics and more risk.
OpenAimei Health is no longer a healthcare-search story. It is a high-risk de-SPAC watch where a small remaining SPAC trust is trying to close a $1.5 billion all-share United Hydrogen transaction.
OpenAdvanced Flower Capital's first quarter as a BDC showed dividend-covering NII and higher NAV, but three nonaccrual loans still represented 36.6% of amortized cost and 23.5% of fair value.
OpenAEXA is not a business yet. It is a NYSE-listed SPAC with $351.4 million in trust, $0.3 million of cash outside trust, no selected target as of March 31, 2026, and public shareholder economics that turn on redemption value, sponsor incentives and the future deal terms.
OpenAeva has the kind of customer list lidar startups chase: Daimler Truck, a Top 10 European OEM, NVIDIA, Forterra, Nikon and smart-infrastructure deployments. The catch is that revenue is still $6.3 million a quarter, broad-based deliveries are not expected in 2026, and the bridge is funded by cash, convertible debt and an equity-linked facility.
OpenAtlas Energy Solutions still depends on Permian completions, proppant volumes and the Dune Express. The new question is whether a 1.4 GW Caterpillar framework and a 120 MW tech-customer PPA can turn AESI into a power supplier before leverage, losses and execution risk catch up.
OpenAES has a large clean-power and utility platform, but the March 2026 $15.00 cash merger agreement changes the public-equity question into a regulatory-close trade backed by a company-disclosed growth-capital problem.
OpenAeries has turned fiscal 2026 adjusted EBITDA positive and sells an AI-enabled GCC model to private-equity and middle-market clients, but the latest filings also show going-concern doubt, Nasdaq delisting proceedings, FPA obligations and control weaknesses.
OpenAeroméxico has premium demand, loyalty scale and record-margin evidence after its U.S. listing, but the Delta JCA, MEX constraints, fuel, FX, engine issues and a negative equity balance sheet make the setup high risk.
Open